Avalyn Pharma Inc. (AVLN)
Avalyn Pharma Inc. operates as a biopharmaceutical firm currently in its clinical development phase. The company's primary focus is on creating inhaled pharmaceutical products to manage rare lung conditions, including pulmonary fibrosis and various other interstitial lung diseases (ILDs). Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar co-founded the enterprise on May 27, 2011, and its corporate headquarters are situated in Boston, Massachusetts.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Avalyn Pharma Inc. Common Stock
NASDAQ:AVLNHealthcare · Medical - Pharmaceuticals
-0.31%$25.63
AH$25.18-1.76%vs close
Mkt Cap$1.14B
Float20.32M
O/S44.33M
Vol
$ Vol
RVOL
Inst Own91.3%
SI11.6%
Earnings
Dilution
Financials Summary
Revenue$0
Net Income-$85.2M
Total Assets$148.88M
Free Cash Flow-$81.83M
Debt & Equity
Total Debt$1.67M
Total Equity-$238.66M
Shares Outstanding
Short Interest
Split History1 split · 1 reverse
- 1:3Reverse splitSep 25, 20073 shares → 1
Balance Sheet Details
Assets$148.88M
Liabilities$387.54M
Accounts Receivable$537K
Accounts Payable$3.76M
Inventory$0
PP&E (Net)$2.32M
Goodwill$0
Intangible Assets$0
Income Statement
| Period | FY 2025 |
|---|---|
| Currency | USD |
| Period Ending | 2025-12-31 |
| Revenue | $0 |
| YoY Growth | - |
| Cost of Revenue | $0 |
| Gross Profit | $0 |
| Gross Margin | - |
| Research and Development | $76.61M |
| Selling, General, and Administrative | $14.68M |
| Other | $0 |
| Total Operating Expenses | $91.29M |
| Operating Income (EBIT) | -$91.29M |
| Operating Margin | - |
| Interest Expense | $0 |
| Interest Income | $6.18M |
| Other Income (Expense) | $6.09M |
| Income Before Tax (EBT) | -$85.2M |
| Income Tax Expense | $0 |
| Net Income | -$85.2M |
| Net Income Margin | - |
| Supplementary Data | |
| EPS | -2.04 |
| Diluted EPS | -2.04 |
| Weighted Average OS | 41.81M |
| EBITDA | -$91.25M |
| EBITDA Margin | - |
Balance Sheet
| Period | FY 2025 |
|---|---|
| Currency | USD |
| Period Ending | 2025-12-31 |
| Assets | |
| Current Assets | |
| Cash and Cash Equivalents | $52.31M |
| Short-Term Investments | $86.04M |
| Cash and Short-Term Investments | $138.36M |
| Accounts Receivable | $537K |
| Inventory | $0 |
| Other Current Assets | $0 |
| Total Current Assets | $143.56M |
| Long-Term Assets | |
| Property, Plant & Equipment Net | $2.32M |
| Goodwill | $0 |
| Intangible Assets | $0 |
| Long-Term Investments | $0 |
| Deferred Tax Assets | $0 |
| Other Long-Term Assets | $3M |
| Total Long-Term Assets | $5.32M |
| Other Assets | $0 |
| Total Assets | $148.88M |
| Liabilities | |
| Current Liabilities | |
| Accounts Payable | $3.76M |
| Short-Term Debt | $0 |
| Current Income Tax Payable | $0 |
| Current Unearned Revenue | $0 |
| Other Current Liabilities | $4.29M |
| Total Current Liabilities | $14.09M |
| Long-Term Liabilities | |
| Long-Term Debt | $0 |
| Long-Term Unearned Revenue | $0 |
| Long-Term Deferred Tax Liabilities | $0 |
| Other Long-Term Liabilities | $372.22M |
| Total Long-Term Liabilities | $373.45M |
| Other Liabilities | $0 |
| Total Liabilities | $387.54M |
| Stockholders' Equity | |
| Preferred Stock | $0 |
| Common Stock | $24K |
| Retained Earnings | -$265.36M |
| Comprehensive Income & Other | $134K |
| Other Stockholders' Equity | $26.68M |
| Total Equity | -$238.66M |
| Minority Interest | $0 |
| Total Liabilities and Equity | $148.88M |
| Supplementary Data | |
| Total Debt | $1.67M |
| Net Debt | -$50.65M |
Cash Flow Statement
| Period | FY 2025 |
|---|---|
| Currency | USD |
| Period Ending | 2025-12-31 |
| Operating Activities | |
| Net Income | -$85.2M |
| Depreciation & Amortization | $42K |
| Deferred Income Tax | $0 |
| Stock-Based Compensation | $3.27M |
| Changes in Working Capital: | |
| Accounts Receivable | $0 |
| Inventory | $0 |
| Accounts Payable | $1.4M |
| Other Working Capital | $1.22M |
| Total Working Capital Change | $2.61M |
| Other Non-Cash Items | -$2.21M |
| Net Cash from Operating | -$81.48M |
| Investing Activities | |
| Capital Expenditures | -$344K |
| Acquisitions | $0 |
| Purchases of Investments | -$109.3M |
| Sales of Investments | $119.7M |
| Other Investing Activities | $0 |
| Net Cash from Investing | $10.06M |
| Financing Activities | |
| Debt Repaid | - |
| Common Stock Issuance | $18K |
| Common Stock Repurchases | $0 |
| Dividends Paid | $0 |
| Other Financing Activities | -$594K |
| Net Cash from Financing | $99.79M |
| Forex Effect | $0 |
| Net Change in Cash | $28.36M |
| Supplementary Data | |
| Operating Cash Flow | -$81.48M |
| Capital Expenditure | -$344K |
| Free Cash Flow | -$81.83M |
| Cash at Beginning | $23.95M |
| Cash at End | $52.31M |